Back to Search
Start Over
The rationale of dose-response curves in selecting cancer drug dosing.
- Source :
-
British journal of clinical pharmacology [Br J Clin Pharmacol] 2019 Oct; Vol. 85 (10), pp. 2198-2204. Date of Electronic Publication: 2019 Jun 20. - Publication Year :
- 2019
-
Abstract
- Drug development for cancer chemotherapy has an interesting history. A mix of serendipity, animal, cell line, and standard pharmacological principles of dose, dose-response, dose-concentration, dose intensity and combination therapies have been used to develop optimal dosing schedules. However in practice, significant gaps in the translation of preclinical to clinical dosing schedules persist, and clinical development has instead moved to new drug development. A older chemotherapies are still the backbone of most solid tumour schedules, therapeutic drug monitoring has emerged as a method for optimising the dose for individual patients.<br /> (© 2019 The British Pharmacological Society.)
Details
- Language :
- English
- ISSN :
- 1365-2125
- Volume :
- 85
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- British journal of clinical pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 31077412
- Full Text :
- https://doi.org/10.1111/bcp.13979